On Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) was -0.09% drop from the session before ,before settling in for the closing price of $156.04. A 52-week range for ALNY has been $143.52 – $218.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 97.61% over the past five years. When this article was written, the company’s average yearly earnings per share was at -13.22%. With a float of $125.26 million, this company’s outstanding shares have now reached $125.79 million.
Let’s look at the performance matrix of the company that is accounted for 2100 employees.
Alnylam Pharmaceuticals Inc (ALNY) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Alnylam Pharmaceuticals Inc stocks. The insider ownership of Alnylam Pharmaceuticals Inc is 0.54%, while institutional ownership is 93.66%. The most recent insider transaction that took place on Feb 29 ’24, was worth 4,540,071. In this transaction Director of this company sold 30,000 shares at a rate of $151.34, taking the stock ownership to the 0 shares. Before that another transaction happened on Feb 28 ’24, when Company’s Chief Executive Officer sold 2,932 for $155.31, making the entire transaction worth $455,357. This insider now owns 48,128 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted -$1.1 earnings per share (EPS) during the time that was better than consensus figure (set at -$1.32) by $0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.22% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
You can see what Alnylam Pharmaceuticals Inc (ALNY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.74. Likewise, its price to free cash flow for the trailing twelve months is 468.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.56, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -1.90 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) saw its 5-day average volume 0.51 million, a negative change from its year-to-date volume of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 77.61%. Additionally, its Average True Range was 4.42.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 22.16%, which indicates a significant decrease from 78.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 26.55% in the past 14 days, which was lower than the 35.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $156.64, while its 200-day Moving Average is $175.79. Nevertheless, the first resistance level for the watch stands at $158.53 in the near term. At $161.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $162.98. If the price goes on to break the first support level at $154.08, it is likely to go to the next support level at $152.26. Assuming the price breaks the second support level, the third support level stands at $149.63.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are 125,946K outstanding shares of the company, which has a market capitalization of 19.64 billion. As of now, sales total 1,828 M while income totals -440,240 K. Its latest quarter income was 439,720 K while its last quarter net income were -137,870 K.
